JPWO2020092850A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020092850A5 JPWO2020092850A5 JP2021548569A JP2021548569A JPWO2020092850A5 JP WO2020092850 A5 JPWO2020092850 A5 JP WO2020092850A5 JP 2021548569 A JP2021548569 A JP 2021548569A JP 2021548569 A JP2021548569 A JP 2021548569A JP WO2020092850 A5 JPWO2020092850 A5 JP WO2020092850A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- cells
- car
- pharmaceutical composition
- exon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 description 56
- 102100006400 CSF2 Human genes 0.000 description 54
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 54
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 238000000692 Student's t-test Methods 0.000 description 14
- 229920000033 CRISPR Polymers 0.000 description 12
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 12
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 12
- 230000005591 charge neutralization Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000001264 neutralization Effects 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 210000001744 T-Lymphocytes Anatomy 0.000 description 10
- 108090001123 antibodies Proteins 0.000 description 10
- 102000004965 antibodies Human genes 0.000 description 10
- 210000004556 Brain Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000002966 Serum Anatomy 0.000 description 8
- 102100005826 CD19 Human genes 0.000 description 6
- 101700087100 CD19 Proteins 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 206010018987 Haemorrhage Diseases 0.000 description 5
- 230000000740 bleeding Effects 0.000 description 5
- 231100000319 bleeding Toxicity 0.000 description 5
- 102100003268 CD14 Human genes 0.000 description 4
- 101700027514 CD14 Proteins 0.000 description 4
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- 210000003462 Veins Anatomy 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000000306 recurrent Effects 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 102100019461 CD28 Human genes 0.000 description 3
- 101700033362 CD28 Proteins 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 102100019441 ITGAM Human genes 0.000 description 3
- 101710006572 ITGAM Proteins 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 230000002887 neurotoxic Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 206010052015 Cytokine release syndrome Diseases 0.000 description 2
- 229920002391 Guide RNA Polymers 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 210000001616 Monocytes Anatomy 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 206010014599 Encephalitis Diseases 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 229950007439 Lenzilumab Drugs 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007125 Neurotoxicity Syndrome Diseases 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 238000003559 rna-seq method Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753485P | 2018-10-31 | 2018-10-31 | |
| US62/753,485 | 2018-10-31 | ||
| PCT/US2019/059275 WO2020092850A1 (en) | 2018-10-31 | 2019-10-31 | Materials and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513412A JP2022513412A (ja) | 2022-02-07 |
| JPWO2020092850A5 true JPWO2020092850A5 (de) | 2022-11-04 |
Family
ID=70463979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548569A Pending JP2022513412A (ja) | 2018-10-31 | 2019-10-31 | 癌を治療するための物質及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20220040229A1 (de) |
| EP (2) | EP3873205A4 (de) |
| JP (1) | JP2022513412A (de) |
| KR (1) | KR20210105344A (de) |
| CN (1) | CN113194715B (de) |
| AU (1) | AU2019374102A1 (de) |
| BR (1) | BR112021008263A2 (de) |
| CA (1) | CA3116412A1 (de) |
| IL (1) | IL282478A (de) |
| MX (1) | MX2021004993A (de) |
| SG (1) | SG11202103589XA (de) |
| WO (2) | WO2020092850A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020092850A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| WO2022266538A2 (en) * | 2021-06-18 | 2022-12-22 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing or modifying human genes |
| WO2023081252A1 (en) * | 2021-11-03 | 2023-05-11 | Mayo Foundation For Medical Education And Research | Methods and materials for improving t cell therapies |
| CN114606237A (zh) * | 2022-05-11 | 2022-06-10 | 上海优替济生生物医药有限公司 | Gm-csf抑制剂及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US674A (en) | 1838-04-05 | Draft-box eob steam-engines | ||
| US9017A (en) | 1852-06-15 | Cast-iron cab-wheel | ||
| RS55526B1 (sr) * | 2006-02-08 | 2017-05-31 | Morphotek Inc | Antigenski gm-csf peptidi i antitela gm-csf |
| US20100055116A1 (en) * | 2006-04-13 | 2010-03-04 | Liou Hsiou-Chi | Methods and Compositions for Targeting c-Rel |
| CN101165070B (zh) * | 2006-10-20 | 2010-12-08 | 余波 | 一系列双重生物活性的融合蛋白及其医疗应用 |
| EP2101780B1 (de) * | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Verfahren zur behandlung chronischer entzündungskrankheiten mithilfe eines gm-csf-agonisten |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| KR101824512B1 (ko) | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
| US20140127814A1 (en) * | 2010-08-10 | 2014-05-08 | Srinivasan Chandrasegaran | Generation and use of pluripotent stem cells |
| AU2012280267B2 (en) * | 2011-07-06 | 2016-04-21 | Morphosys Ag | Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof |
| DK4019041T3 (da) * | 2012-07-13 | 2023-04-03 | Univ Pennsylvania | Toksicitetshåndtering for cars antitumoraktivitet |
| LT2961831T (lt) * | 2013-02-26 | 2020-11-10 | Memorial Sloan Kettering Cancer Center | Kompozicijos ir būdai, skirti imunoterapijai |
| WO2014172470A2 (en) * | 2013-04-16 | 2014-10-23 | Whitehead Institute For Biomedical Research | Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| EP3071687B1 (de) * | 2013-11-22 | 2019-07-31 | Cellectis | Verfahren zur manipulation chemotherapie-arzneimittelresistenter t-zellen zur immuntherapie |
| JP6202339B2 (ja) * | 2013-12-19 | 2017-09-27 | 国立研究開発法人国立精神・神経医療研究センター | ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤 |
| TR201819571T4 (tr) * | 2014-02-14 | 2019-01-21 | Cellectis | Hem immün hücrelerde hem de patolojik hücrelerde bulunan antijenleri hedef almak amacıyla değiştirilmiş immünoterapiye yönelik hücreler. |
| EP3129470B1 (de) * | 2014-04-07 | 2021-04-07 | Novartis Ag | Behandlung von krebs mittels chimärem anti-cd19-antigenrezeptor |
| PL3169341T3 (pl) * | 2014-07-16 | 2019-12-31 | Transgene Sa | Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej |
| US10507219B2 (en) * | 2014-10-20 | 2019-12-17 | Juno Therapeutics, Inc. | Methods and compositions for dosing in adoptive cell therapy |
| US10688166B2 (en) * | 2014-11-03 | 2020-06-23 | Cerus Corporation | Compositions and methods for improved car-T cell therapies |
| CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| US11747346B2 (en) * | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| CA2999500A1 (en) * | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| EA201891092A1 (ru) * | 2015-11-04 | 2018-10-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способы и композиции для редактирования генов в гемопоэтических стволовых клетках |
| EP4012415A3 (de) * | 2015-12-04 | 2022-12-07 | Juno Therapeutics, Inc. | Verfahren und zusammensetzungen in zusammenhang mit zelltherapieassoziierter toxizität |
| US11730761B2 (en) * | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN106399375A (zh) * | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法 |
| EP3580236A4 (de) * | 2017-02-07 | 2020-12-09 | ME Therapeutics Inc. | Anti-g-csf-antikörper und verwendungen dafür |
| CN107271675B (zh) * | 2017-03-24 | 2020-06-02 | 郑猛 | 抗人adrb3单克隆抗体及其在疾病诊断和治疗中的应用 |
| JP7411578B2 (ja) * | 2018-06-01 | 2024-01-11 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 癌を治療するための物質及び方法 |
| EP3849572A4 (de) * | 2018-09-10 | 2022-07-13 | Humanigen, Inc. | Verfahren zur behandlung von mit immuntherapie einhergehender toxizität unter verwendung eines gm-csf-antagonisten |
| WO2020092850A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| US20220331425A1 (en) * | 2019-06-03 | 2022-10-20 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
-
2019
- 2019-10-31 WO PCT/US2019/059275 patent/WO2020092850A1/en unknown
- 2019-10-31 CN CN201980072681.3A patent/CN113194715B/zh active Active
- 2019-10-31 SG SG11202103589XA patent/SG11202103589XA/en unknown
- 2019-10-31 JP JP2021548569A patent/JP2022513412A/ja active Pending
- 2019-10-31 EP EP19880756.2A patent/EP3873205A4/de active Pending
- 2019-10-31 AU AU2019374102A patent/AU2019374102A1/en not_active Abandoned
- 2019-10-31 CA CA3116412A patent/CA3116412A1/en active Pending
- 2019-10-31 MX MX2021004993A patent/MX2021004993A/es unknown
- 2019-10-31 BR BR112021008263-8A patent/BR112021008263A2/pt not_active Application Discontinuation
- 2019-10-31 US US17/290,185 patent/US20220040229A1/en active Pending
- 2019-10-31 KR KR1020217016530A patent/KR20210105344A/ko unknown
-
2021
- 2021-03-22 US US17/209,160 patent/US20210284714A1/en active Pending
- 2021-04-20 IL IL282478A patent/IL282478A/en unknown
-
2022
- 2022-03-15 EP EP22776332.3A patent/EP4314037A1/de active Pending
- 2022-03-15 US US18/283,196 patent/US20240158467A1/en active Pending
- 2022-03-15 WO PCT/US2022/020459 patent/WO2022203908A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11254912B2 (en) | Methods and compositions for treating cancer | |
| JP7411578B2 (ja) | 癌を治療するための物質及び方法 | |
| Tomuleasa et al. | Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia | |
| US20220226375A1 (en) | Anti-cd33 immune cell cancer therapy | |
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| US20210284714A1 (en) | Materials and methods for treating cancer | |
| US20200140815A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| JP2022512922A (ja) | キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法 | |
| JP2023547695A (ja) | 増強された免疫療法のためのシステムおよび方法 | |
| US20200281977A1 (en) | Nk or t cells and uses thereof | |
| WO2022228471A1 (zh) | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 | |
| CN111902532A (zh) | 用于癌症治疗的精氨酸酶抑制 | |
| JPWO2020092850A5 (de) | ||
| EP1028754A1 (de) | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen | |
| JPWO2021136263A5 (de) | ||
| JP7439280B2 (ja) | キメラ抗原受容体の最適化 | |
| JPH11509415A (ja) | 成熟ｔリンパ球中での特異的発現を制御するｃｄ４遺伝子由来の配列 | |
| CN117778328A (zh) | 一种通用型bcma car-t细胞的增殖方法 |